Last reviewed · How we verify
Prevnar (PCV7)
Prevnar (PCV7) is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against seven serotypes of Streptococcus pneumoniae.
Prevnar (PCV7) is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against seven serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in infants and young children, Prevention of pneumococcal otitis media in infants and young children.
At a glance
| Generic name | Prevnar (PCV7) |
|---|---|
| Also known as | 7-valent pneumococcal conjugate vaccine, PCV7, Prevnar |
| Sponsor | University of Minnesota |
| Drug class | Pneumococcal conjugate vaccine |
| Target | Streptococcus pneumoniae polysaccharide antigens (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
PCV7 works by conjugating polysaccharide antigens from seven pneumococcal serotypes to a protein carrier (diphtheria toxoid), which enhances T-cell dependent immune responses. This conjugation strategy allows the vaccine to elicit both antibody and cellular immunity, providing protection against invasive pneumococcal disease caused by the included serotypes. The vaccine is administered intramuscularly and induces opsonophagocytic antibodies that facilitate bacterial clearance.
Approved indications
- Prevention of invasive pneumococcal disease in infants and young children
- Prevention of pneumococcal otitis media in infants and young children
Common side effects
- Injection site erythema
- Injection site swelling
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002) (PHASE1)
- Nasopharyngeal Carriage of S. Pneumoniae (NA)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 (PHASE3)
- Safety and Efficacy of wSp Vaccine in Young Children (PHASE2)
- Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prevnar (PCV7) CI brief — competitive landscape report
- Prevnar (PCV7) updates RSS · CI watch RSS
- University of Minnesota portfolio CI